John Papp Phones & Addresses
-
Colorado Springs, CO
-
Hyattsville, MD
-
Easton, PA
-
7518 Mandan Rd, Greenbelt, MD 20770 (301) 345-0857
-
6 Ridge Rd, Greenbelt, MD 20770 (301) 441-3286 (301) 441-3510
-
6 Ridge Rd UNIT G, Greenbelt, MD 20770 (301) 441-3286
-
Reston, VA
-
Stewartsville, NJ
Work
Position:
Administration/Managerial
Education
Degree:
Associate degree or higher
Emails
b***c@hotmail.com
Resumes
Resumes
John Papp
View pageLocation:
Colorado Springs, Colorado Area
Industry:
Defense & Space
John Papp
View pageLocation:
United States
Sales Mgr At Kirby Lithographic, Inc.
View pagePosition:
Sales Mgr at Kirby Lithographic, Inc.
Location:
Washington D.C. Metro Area
Industry:
Printing
Work:
Kirby Lithographic, Inc.
Sales Mgr
Sales Mgr
Sales Manager At Kirby Lithographic, Inc.
View pagePosition:
Sales Manager at Kirby Lithographic, Inc.
Location:
Washington D.C. Metro Area
Industry:
Printing
Work:
Kirby Lithographic, Inc.
Sales Manager
Sales Manager
Sales Manager At Kirby Lithographic, Inc.
View pageLocation:
Washington D.C. Metro Area
Industry:
Printing
Publications
Isbn (Books And Publications)
Endoscopic Control of Gastrointestinal Hemorrhage
View page
Author
John P. Papp
ISBN #
0849362954
Us Patents
Methods Of Treatment With Drug Eluting Stents With Prolonged Local Elution Profiles With High Local Concentrations And Low Systemic Concentrations
View pageUS Patent:
20160250049, Sep 1, 2016
Filed:
May 13, 2016
Appl. No.:
15/154773
Inventors:
- Abbott Park IL, US
Winnette S. MCINTOSH - Washington DC, US
Dudley S. JAYASINGHE - Murrieta CA, US
Gregory C. ORR - Escondido CA, US
John E. PAPP - Temecula CA, US
Lewis B. SCHWARTZ - Lake Forest IL, US
Winnette S. MCINTOSH - Washington DC, US
Dudley S. JAYASINGHE - Murrieta CA, US
Gregory C. ORR - Escondido CA, US
John E. PAPP - Temecula CA, US
Lewis B. SCHWARTZ - Lake Forest IL, US
International Classification:
A61F 2/915
Abstract:
A drug eluting stent can include a stent body having a polymeric coating with a lipophilic and/or hydrophilic element. A drug that has a bioactivity that inhibits cell proliferation can be disposed in the polymeric coating. The drug can be present in the polymer at an amount greater than or equal to about 150 μg/cm. The polymeric coating and drug are configured to cooperate so as to form a diffusion pathway with tissue when the stent is disposed in a body lumen such that the drug preferentially diffuses into the tissue over a body fluid passing through the body lumen such that a maximum systemic blood concentration of the drug is less than about 40 ng/ml.